TRAW Earnings — Traws Pharma, Inc. Common Stock Post-ER Performance | BigEarnings
TRAW — Traws Pharma, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$1.46
Market Cap$22.1M
P/E—
52W Range$0.99 – $3.27
Next Earnings2026-08-13
About Traws Pharma, Inc. Common Stock
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
